AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+21.99%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$6.8B
AUM Growth
+$6.8B
(+27%)
Cap. Flow
+$226M
Cap. Flow
% of AUM
3.33%
Top 10 Holdings %
Top 10 Hldgs %
92.21%
Holding
134
New
22
Increased
25
Reduced
13
Closed
23
Top Buys
| 1 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$50.4M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$32.1M |
| 3 |
Nektar Therapeutics
NKTR
|
$31.9M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
$28.6M |
| 5 |
Amicus Therapeutics
FOLD
|
$22.6M |
Top Sells
| 1 |
Neurocrine Biosciences
NBIX
|
$19.4M |
| 2 |
Incyte
INCY
|
$16.7M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$7.25M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$6.8M |
| 5 |
ALDR
Alder Biopharmaceuticals, Inc.
ALDR
|
$5.73M |
Sector Composition
| 1 | Consumer Staples | 51.19% |
| 2 | Consumer Discretionary | 27.58% |
| 3 | Healthcare | 20.59% |
| 4 | Communication Services | 0.17% |
| 5 | Materials | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Bristol-Myers Squibb
BMY
$96.7B
| – | – |
0
| – | – |
|
127
BioMarin Pharmaceuticals
BMRN
$11.3B
| – | – |
0
| – | – |
|
128
Brighthouse Financial
BHF
$2.55B
| – | – |
0
| – | – |
|
129
BioCryst Pharmaceuticals
BCRX
$1.74B
| – | – |
-500,000
| Closed | -$2.46M |
|
130
Bank of America
BAC
$371B
| – | – |
0
| – | – |
|
131
Alibaba
BABA
$325B
| – | – |
0
| – | – |
|
132
Amgen
AMGN
$153B
| – | – |
0
| – | – |
|
|
ADAP
133
Adaptimmune Therapeutics
ADAP
$13.9M
| – | – |
-700,000
| Closed | -$4.68M |
|
134
Celldex Therapeutics
CLDX
$1.57B
| – | – |
-350,336
| Closed | -$995K |
|